Sign up for email alert when new content gets added: Sign up
OBJECTIVES: To evaluate the satisfaction, preferences and adherence of patients treated with the Spanish National Cardiovascular Research Centre (CNIC) polypill containing acetylsalicylic acid (ASA) 100 mg, atorvastatin 20 mg and ramipril 2.5;5;10 mg compared with patients with ASA, a statin and an angiotensin converting enzyme (ACE) inhibitor separately, for secondary prevention of cardiovascular disease (CVD).
DESIGN: An observational, cross-sectional, cohort, multicenter study was conducted in Spain and Belgium. Two cohorts were included: patients treated with CNIC polypill or trated with the monocomponents separately. Patients had to have a history of CVD (>1 year from the last CV event) and had to be treated with the current treatment for a minimum of 3 months prior to enrolment. Patients from both cohorts were paired based on gender and age.
METHODS: Satisfaction was evaluated by the TSQM-9, adherence by the Morisky-Green questionnaire and ad hoc questions were asked to determine patient preferences.
RESULTS: 366 patients were included and 335 were analyzed. Patients treated with the CNIC polypill reported higher level of satisfaction than patients treated with the monocomponents (77.3% vs. 71.2%, p <0.0001). 72.8% of patients treated with the monocomponents would prefer to change to the polypill. Patients treated with the polypill had significantly higher adherence than patients treated with the monocomponents (57.7% vs. 41.1%) (p=0.0027).
CONCLUSION: Patients treated with the CNIC polypill showed a significantly higher degree of satisfaction and better adherence, whereas most patients receiving the monocomponents would prefer to be treated with a polypill regime.